Shares of AbbVie (NYSE:ABBV) are surging 7% this morning after the pharmaceutical giant reported solid fourth quarter earnings as two key immunology drugs continue to enjoy significant support.

AbbVie (ABBV) closed the latest trading day at $213.59, indicating a -1.42% change from the previous session's end. The stock fell short of the S&P 500, which registered a loss of 0.76% for the day.

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other S&P 500 dividend aristocrats sorted by hedge fund sentiment. Dividend Aristocrats are companies ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks. Lee Munder Capital Group Investments, more commonly known as LMCG Investments ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other stocks. Some of the major U.S. indexes began recovering on Wednesday, following the Trump ...

Since the publication of my article "Top 4 Immunology Stocks Poised For Growth In 2025," AbbVie's stock price (NYSE:ABBV) has risen by over 17%. The first reason is that the North Chicago-based ...

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune ...

Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of ...

My last analyses on Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) were both published before the release of their earnings. Furthermore, both articles placed an emphasis on dividends.